respiratori
viral
infect
rvi
associ
wide
rang
clinic
manifest
rang
selflimit
upper
respiratori
tract
infect
devast
condit
pneumonia
rvi
constitut
frequent
reason
medic
consult
world
consider
impact
qualiti
life
product
therefor
prevent
control
rvi
remain
major
clinic
goal
current
approxim
known
respiratori
virus
group
one
famili
dna
virus
adenovirida
four
famili
rna
virus
orthomyxovirida
paramyxovirida
picornavirida
coronavirida
paper
review
major
respiratori
virus
caus
disesas
human
emphasi
current
treatment
option
respiratori
viral
infect
rvi
frequent
reason
medic
consult
world
anzueto
niederman
associ
wide
rang
clinic
manifest
selflimit
infect
upper
respiratori
tract
devast
condit
affect
lower
respiratori
tract
pneumonia
addit
rvi
consider
impact
qualiti
life
product
societi
exampl
unit
state
alon
infect
respons
million
absenc
work
million
absenc
school
everi
year
brook
et
al
annual
burden
epidem
influenza
alon
averag
million
physician
visit
hospit
death
cdc
unit
state
cost
noninfluenzarel
rvi
may
reach
billion
dollar
annual
fenderick
et
al
year
consum
spend
billion
dollar
myriad
product
market
treat
cold
symptom
antihistamin
analges
antituss
antiinflammatori
agent
temt
follow
consider
research
progress
respiratori
virus
speci
rhinovirus
coronavirus
enterovirus
adenovirus
parainfluenza
virus
respiratori
syncyci
virus
ad
influenza
virus
caus
respiratori
tract
infect
recent
identifi
respiratori
virus
human
metapneumoviru
van
den
hoogen
et
boivin
et
al
human
ito
et
al
boivin
et
al
new
human
coronavirus
hcov
one
associ
sever
acut
respiratori
syndrom
sar
ksiazek
et
al
well
hcovnl
fouchier
et
al
woo
et
al
b
import
addit
list
current
approxim
known
virus
typic
produc
respiratori
syndrom
group
five
viral
famili
includ
one
famili
dna
virus
adenovirida
four
famili
rna
virus
orthomyxovirida
paramyxovirida
picornavirida
coronavirida
tabl
purpos
paper
review
major
respiratori
virus
caus
diseas
human
emphasi
current
therapeut
option
orthomyxovirus
envelop
negativesens
rna
virus
contain
rna
segment
code
protein
hayden
pales
rna
protect
close
associ
nucleoprotein
form
helic
structur
call
nucleocapsid
nc
base
nc
matrix
antigen
influenza
virus
classifi
three
genera
influenza
b
c
virus
influenza
virus
contain
two
import
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
respons
viru
attach
hostcel
receptor
virion
releas
infect
cell
respect
antigen
differ
ha
na
protein
provid
classif
influenza
virus
ha
na
subtyp
subtyp
identifi
bird
wherea
known
infect
pig
hors
whale
hayden
pales
past
centuri
ha
na
subtyp
effici
infect
human
influenza
virus
spread
respiratori
droplet
result
spectrum
clinic
respons
rang
mildli
symptomat
infect
primari
viral
pneumonia
rapidli
progress
death
lamb
webster
influenza
virus
usual
associ
sever
outcom
b
c
virus
typic
influenza
syndrom
consist
tracheobronch
addit
involv
small
airway
lamb
webster
incub
period
averag
day
wherea
viral
shed
respiratori
tract
secret
gener
last
day
immunocompet
adult
onset
ill
usual
abrupt
occurr
headach
chill
dri
cough
follow
high
fever
signific
myalgia
malais
anorexia
usual
benign
complic
influenza
includ
sinus
otiti
media
bronchiti
sever
complic
viral
andor
bacteri
pneumonia
well
exacerb
underli
ill
may
also
occur
particularli
young
children
elderli
subject
cardiopulmonari
diseas
immunosuppress
wright
webster
although
annual
immun
program
use
inactiv
trival
vaccin
remain
import
mean
reduc
influenzarel
morbid
mortal
certain
condit
antivir
agent
warrant
treatment
andor
prevent
diseas
individu
vaccin
mount
adequ
immun
respons
vaccin
year
mismatch
circul
vaccin
viral
strain
advent
new
pandem
strain
pend
avail
adequ
vaccin
amantadin
hydrochlorid
symmetrel
analogu
rimantadin
flumadin
constitut
first
class
antivir
licens
influenza
infect
agent
inhibit
earli
step
influenza
viru
replic
cycl
interf
function
viral
protein
fig
latter
act
ion
channel
hydrogen
ion
pass
interstic
viral
particl
result
dissoci
matrix
protein
ribonucleoprotein
rnp
complex
rnp
enter
cell
nucleu
initi
replic
martin
heleniu
amantadin
rimantadin
effect
low
dose
variou
subtyp
influenza
virus
wherea
activ
influenza
b
virus
cell
cultur
experi
concentr
amantadin
inhibit
influenza
viru
plaqu
format
vari
gml
hayden
pales
pharmacokinet
amantadin
rimantadin
administ
oral
tablet
syrup
dose
mgkg
bodi
weight
children
mgday
adult
moscona
drug
absorb
rapidli
nearli
complet
peak
plasma
concentr
reach
within
h
amantadin
h
rimantadin
couch
amantadin
rimantadin
mostli
metabol
highli
excret
urin
amantadin
halflif
h
young
adult
elderli
subject
respect
wherea
rimantadin
halflif
averag
h
group
couch
clinic
efficaci
amantadin
rimantadin
effect
prevent
influenza
infect
ill
hayden
pales
use
prophylact
either
drug
prevent
infect
ill
couch
demich
et
al
estim
averag
effect
amantadin
rimantadin
prevent
confirm
influenza
ill
respect
therapeut
use
drug
also
associ
reduct
durat
symptom
approxim
day
administ
within
h
onset
symptom
couch
howev
drug
shown
prevent
complic
associ
influenza
infect
monto
bridg
et
al
side
effect
amantadin
caus
central
nervou
system
cn
symptom
anxieti
depress
insomnia
subject
wherea
cn
symptom
report
individu
treat
rimantadin
couch
besid
cn
symptom
amantadin
rimantadin
caus
transient
gastrointestin
symptom
includ
nausea
vomit
couch
resist
adamantan
despit
fact
natur
occur
amantadineresist
influenza
virus
rare
found
rate
resist
exceed
report
day
therapi
klimov
et
al
shiraishi
et
al
hayden
et
al
molecular
character
adamantaneresist
influenza
variant
reveal
singl
substitut
one
five
codon
transmembran
region
protein
may
confer
drug
resist
klimov
et
al
masuda
et
al
boivin
et
al
saito
et
al
recent
report
show
individu
shed
amantadineresist
variant
counterpart
saito
et
al
note
current
avian
influenza
viru
z
strain
emerg
southeast
asia
resist
amantadin
concern
enhanc
fact
adamantaneresist
mutant
virus
found
maintain
good
replic
capac
vitro
least
virul
wildtyp
sensit
virus
anim
model
sweet
et
al
abe
et
al
furthermor
adamantaneresist
influenza
virus
transmiss
human
hayden
et
al
mechan
action
nai
target
activ
site
na
enzym
highli
conserv
influenza
b
virus
nai
inhibit
cleavag
termin
sialic
acid
residu
attach
viral
glycoprotein
cellular
glycolipid
fig
process
necessari
releas
influenza
virion
host
cell
spread
viru
throughout
respiratori
mucu
pales
compan
zanamivir
oseltamir
excel
vitro
activ
nine
na
subtyp
influenza
na
influenza
b
virus
mendel
robert
notabl
drug
effect
avian
virus
subtyp
although
higher
dose
prolong
treatment
oseltamivir
requir
achiev
inhibit
virus
mice
yen
et
al
zanamivir
valu
clinic
isol
vari
wide
use
plaqu
reduct
assay
pra
madin
darbi
canin
kidney
mdck
cell
nm
fall
much
narrow
rang
nm
directli
test
inhibit
na
activ
use
enzymat
assay
whetheral
et
al
zanamivir
exhibit
better
vitro
antivir
activ
influenza
b
virus
wherea
oseltamivir
lower
valu
influenza
isol
boivin
goyett
whetheral
et
al
pharmacokinet
zanamivir
relenza
commerci
avail
drug
powder
inhal
oral
administr
diskhal
dose
zanamivir
deposit
oropharynx
wherea
reach
lung
cass
et
al
ten
inhal
dose
bioavail
howev
concentr
drug
respiratori
tract
estim
time
valu
influenza
b
virus
peng
et
al
absorb
drug
excret
urin
without
metabol
chang
cass
et
al
oseltamivir
tamiflu
avail
oral
administr
capsul
liquid
suspens
ethyl
ester
prodrug
convert
activ
form
oseltamivir
carboxyl
ester
hydrolysi
gut
kim
et
al
dose
wide
distribut
bodi
allow
drug
activ
outsid
respiratori
tract
moscona
oseltamivir
carboxyl
excret
mainli
kidney
therefor
dose
must
reduc
patient
advanc
renal
insuffici
creatinin
clearanc
mlmin
moscona
zanamivir
oseltamivir
effect
prevent
influenza
infect
tabl
zanamivir
provid
reduct
incid
laboratoryconfirm
symptomat
influenza
season
prophylaxi
commun
monto
et
al
postexposur
prophylaxi
household
oseltamivir
reduc
incid
laboratoryconfirm
influenza
season
prophylaxi
commun
institution
elderli
subject
peter
et
al
use
postexposur
prophylaxi
household
oseltamivir
associ
reduct
incid
laboratoryconfirm
influenza
individu
year
old
number
household
respect
welliv
et
al
effect
oseltamivir
postexposur
prophylaxi
children
year
old
also
demonstr
although
drug
current
approv
prophylaxi
children
older
year
zanamivir
oseltamivir
also
effect
treatment
influenza
infect
tabl
zanamivir
dose
mg
twice
daili
day
start
within
h
onset
symptom
reduc
durat
symptom
natur
occur
influenza
infect
day
adult
monto
et
al
hayden
et
al
mist
studi
group
makela
et
al
boivin
et
al
children
year
old
zanamivir
reduc
durat
symptom
day
hedrick
et
al
metaanalysi
random
adultspep
household
metaanalysi
cooper
et
al
placebocontrol
trial
also
demonstr
zanamivir
confer
reduct
durat
symptom
day
reduct
complic
highrisk
patient
confirm
influenza
infect
lalezari
et
al
similarli
oseltamivir
effect
treatment
natur
occur
influenza
infect
adult
nicholson
et
al
treanor
et
al
aoki
et
al
patient
treat
either
mg
recommend
dose
mg
oseltamivir
bid
day
median
time
allevi
symptom
reduc
day
respect
nicholson
et
al
adult
adolesc
proven
influenza
ill
oseltamivir
treatment
reduc
incid
influenzarel
lower
respiratori
tract
complic
antibiot
use
respect
kaiser
et
al
children
year
old
oseltamivir
treatment
reduc
median
durat
ill
day
afford
reduct
cough
coryza
fever
whitley
et
al
incid
antibiot
prescript
also
significantli
reduc
oseltamivir
group
compar
placebo
group
maxim
benefit
antivir
treatment
must
start
earli
possibl
within
h
onset
symptom
inde
everi
h
reduct
oseltamivir
treatment
initi
time
compar
symptom
onset
median
ill
durat
could
shorten
h
aoki
et
al
unit
state
america
zanamivir
approv
treatment
individu
year
mg
twice
daili
day
wherea
oseltamivir
licens
treatment
person
year
mg
twice
daili
day
moscona
minor
side
effect
report
less
person
given
zanamivir
clinic
trial
includ
transient
upper
respiratori
gastrointestin
symptom
moscona
nevertheless
zanamivir
use
caution
patient
chronic
respiratori
diseas
sinc
caus
bronchospasm
reduct
air
flow
couch
oseltamivir
also
side
effect
transient
nausea
vomit
abdomin
pain
occur
treat
person
couch
side
abe
et
al
gubareva
et
al
na
mutat
associ
nai
resist
subtypespecif
drugspecif
involv
catalyt
framework
residu
tabl
mutat
codon
predomin
virus
wherea
mutat
number
frequent
virus
whitley
et
al
wang
et
al
weinstock
et
al
note
last
mutat
report
virus
isol
asia
le
et
al
de
jong
et
al
unlik
amantadineresist
variant
nairesist
influenza
virus
infrequ
clinic
trial
estim
rate
resist
vari
adult
popul
children
robert
howev
higher
rate
oseltamivir
resist
report
recent
treatment
studi
japanes
children
kiso
et
al
probabl
nairesist
variant
seem
compromis
regard
infect
transmiss
mice
ferret
herloch
et
al
far
resist
zanamivir
extrem
infrequ
one
case
report
immunocompromis
child
infect
influenza
b
gubareva
et
al
whether
lower
rate
resist
due
intrins
drug
properti
lower
use
compound
compar
oseltamivir
clarifi
besid
zanamivir
oseltamivir
compound
target
na
enzym
influenza
virus
develop
although
commerci
avail
peramivir
oral
bioavail
cyclopentan
compound
potent
na
inhibitor
vitro
vivo
sidwel
smee
pyrrolidonebas
compound
also
demonstr
vitro
activ
influenza
subtyp
influenza
b
virus
similar
zanamivir
oseltamivir
hanessian
et
al
zanamivir
deriv
compound
contain
differ
sidechain
could
also
consid
possibl
antiinfluenza
agent
de
clerq
efficaci
new
nai
influenza
b
mutant
summar
tabl
final
ribavirin
discuss
vitro
activ
influenza
virus
couch
addit
demonstr
high
efficaci
prevent
death
reduc
lung
viru
titer
mice
infect
influenza
b
virus
sidwel
et
al
viral
famili
contain
import
respiratori
virus
caus
epidem
major
medic
interest
paramyxovirus
singlestrand
negativesens
rna
virus
divid
two
subfamili
fig
paramyxovirus
includ
import
virus
associ
upper
lower
respiratori
tract
infect
human
ie
human
respiratori
syncyci
viru
hrsv
human
parainfluenza
virus
hpiv
human
metapneumoviru
hmpv
unlik
orthomyxovirus
rna
genom
paramyxovirus
segment
encod
sever
subgenom
messeng
rna
mrna
hrsv
subgenom
mrna
translat
protein
includ
nucleocapsid
protein
n
p
l
transmembran
glycoprotein
f
g
sh
nonstructur
protein
matrix
protein
rna
regulatori
factor
compar
hrsv
hmpv
ns
protein
wherea
hpiv
possess
hemagglutininneuraminidas
hn
protein
instead
g
protein
ns
sh
protein
fig
hrsv
major
caus
lower
respiratori
tract
diseas
prematur
babi
month
gestat
infant
less
month
old
elderli
institution
subject
welliv
greenough
outcom
hrsv
infect
usual
involv
mild
upper
respiratori
tract
infect
howev
sever
condit
pneumonia
bronchiol
occur
children
meissner
approxim
hrsvinfect
infant
requir
hospit
greenough
year
us
pediatr
hrsv
infect
associ
hospit
attribut
bronchiol
attribut
pneumonia
ogra
northern
hemispher
particular
us
hrsv
circul
predominantli
winter
month
account
approxim
hospit
death
annual
ogra
thompson
et
al
current
approv
vaccin
hrsv
despit
consider
work
area
ribavirin
ribavirin
virazol
nucleosid
analogu
current
licens
treatment
sever
hrsv
diseas
highrisk
infant
brook
et
al
drug
broad
spectrum
activ
dna
rna
virus
balfour
ribavirin
inhibit
viral
replic
sever
mechan
includ
inhibit
viral
polymeras
inhibit
cap
format
mrna
inhibit
imp
dehydrogenas
lead
decreas
intracellular
gtp
concentr
balfour
despit
initi
promis
clinic
studi
ribavirin
found
confer
clinic
benefit
larg
nonrandom
cohort
studi
previous
healthi
infant
respiratori
failur
due
hrsv
infect
moler
et
al
clinic
impact
ribavirin
treatment
hrsv
lower
respiratori
tract
infect
infant
children
also
evalu
metaanalysi
control
trial
vuvoj
mill
drug
provid
signific
reduct
durat
assist
ventil
wherea
signific
impact
mortal
rate
length
hospit
pulmonari
function
american
academi
pediatr
revis
recommend
replac
statement
ribavirin
use
ribavirin
may
consid
infant
young
children
risk
sever
hrsv
diseas
nevertheless
ribavirin
therapi
remain
recommend
highrisk
patient
hrsv
infect
associ
signific
rate
mortal
bone
marrow
transplant
recipi
moscona
englund
et
al
ribavirin
highli
toxic
bone
marrow
progenitor
administ
aerosol
form
treatment
respiratori
tract
infect
hrsv
f
protein
constitut
two
subunit
subunit
contain
two
heptad
repeat
region
highli
conserv
among
paramyxovirus
conform
chang
f
protein
lead
format
stabl
sixhelix
bundl
respons
fusion
viral
cellular
membran
zhao
et
al
therefor
region
seem
suitabl
target
develop
antihrsv
agent
recombin
protein
express
e
coli
show
strong
inhibitori
effect
hrsv
fusion
valu
respect
wang
et
al
recent
sever
small
molecul
potent
inhibitori
effect
hrsv
fusion
identifi
triphenyl
compound
viropharma
benzimidazol
analogu
johnson
johnson
small
molecul
bind
hydrophob
caviti
inner
core
f
protein
interact
simultan
dougla
et
al
agent
effici
inhibit
hrsv
infect
vitro
valu
nm
respect
dougla
et
al
cell
fusion
assay
valu
agent
nm
respect
character
drugresist
hrsv
variant
select
vitro
presenc
inhibitor
reveal
amino
acid
chang
interven
domain
dougla
et
al
vitro
studi
show
substitut
residu
involv
direct
contact
bound
inhibitor
could
respons
resist
phenotyp
dougla
et
al
polynuclear
aromat
compound
wyeth
also
potent
antihrsv
activ
block
two
viral
f
glycoproteinmedi
fusion
event
includ
fusion
virion
envelop
cellular
plasma
membran
syncytium
format
huntley
et
al
vitro
inhibit
hrsv
b
replic
averag
valu
rang
gml
huntley
et
al
addit
african
green
monkey
model
prophylact
administr
result
reduct
viru
lung
titer
log
day
post
hrsv
challeng
antisens
oligodeoxynucleotid
odn
short
nucleotid
singlestrand
molecul
design
inhibit
rna
express
anneal
complementari
region
target
mrna
newli
form
rnadna
hybrid
attract
endogen
ribonucleas
h
rnase
h
cleav
rna
portion
hybrid
crook
result
transcript
degrad
andor
prevent
translat
protein
phosphorothio
odn
target
hrsv
repetit
intergen
site
shown
potent
vitro
activ
jairath
et
al
two
immunoprophylact
agent
approv
prevent
hrsv
diseas
respigam
intraven
polyclon
immun
globulin
enrich
neutral
antibodi
hrsv
recommend
prevent
seriou
hrsv
diseas
highrisk
infant
respigam
reduc
hospit
hospit
stay
total
hrsvrelat
intens
care
unit
day
respect
maggon
barik
howev
product
requir
larg
volum
infus
avail
current
limit
palivizumab
synagi
monoclon
antibodi
compos
human
murin
antibodi
sequenc
direct
hrsv
fusion
f
glycoprotein
meissner
johnson
et
al
palivizumab
time
potent
respigam
approv
us
food
drug
administr
fda
prevent
seriou
lower
respiratori
tract
infect
caus
hrsv
palivizumab
recommend
hrsv
season
monthli
intramuscular
inject
prematur
babi
week
gestat
infant
younger
year
age
chronic
lung
diseas
congenit
heart
diseas
phase
iii
clinic
studi
involv
highrisk
infant
palivizumab
reduc
incid
hospit
impactrsv
studi
group
anoth
doubleblind
random
placebocontrol
studi
children
congenit
heart
diseas
show
reduct
hospit
treat
group
felt
et
al
hand
palivizumab
seem
provid
direct
cost
save
relat
hospit
ambulatori
care
infant
born
week
estim
gestat
age
wegner
et
al
possibl
effect
glucocorticoid
therapi
improv
pulmonari
inflammatori
respons
hrsv
infect
suggest
vuvoj
mill
metaanalysi
six
random
control
trial
system
corticosteroid
use
bronchiol
show
durat
symptom
length
hospit
stay
significantli
reduc
corticosteroid
treatment
garrison
et
al
howev
subsequ
random
doubleblind
placebocontrol
trial
demonstr
dexamethason
impair
declin
hrsv
lower
respiratori
tract
infant
sever
hrsv
diseas
associ
improv
clinic
outcom
buckingham
et
al
four
distinct
serotyp
human
parainfluenza
virus
describ
henrickson
virus
caus
upper
respiratori
tract
diseas
individu
age
group
although
young
children
month
year
present
sever
diseas
henrickson
us
hpiv
account
approxim
lower
respiratori
tract
infect
children
younger
year
denni
clyde
glezen
et
al
report
caus
diseas
fall
month
altern
year
knott
et
al
reed
et
al
wherea
appear
endem
month
year
hpiv
associ
laryngotracheobronch
croup
mainli
bronchiol
pneumonia
henrickson
present
time
exist
licens
hpiv
vaccin
although
recombin
liveattenu
vaccin
combin
hrsv
glycoprotein
induc
satisfactori
immun
respons
current
antivir
approv
treatment
hpiv
infect
although
sever
compound
demonstr
vitro
andor
vivo
activ
virus
henrickson
brown
plaqu
inhibit
experi
drug
reduc
plaqu
format
concentr
approxim
gml
respect
brown
aerosol
oral
ribavirin
also
associ
reduct
hpiv
shed
clinic
improv
infect
immunocompromis
patient
chakrabarti
et
al
malinowski
hostoff
hn
hpiv
respons
viru
bind
host
cell
promot
f
proteinmedi
fusion
addit
facilit
spread
infect
na
activ
cleav
receptor
thu
prevent
virion
aggreg
henrickson
zanamivir
inhibit
na
valu
na
assay
greengard
et
al
note
drug
approxim
time
less
activ
compar
influenza
virus
two
novel
hpiv
inhibitor
target
hn
protein
demonstr
potent
vitro
activ
cell
valu
ha
inhibit
assay
na
inhibit
assay
alymova
et
al
addit
agent
associ
signific
reduct
viral
lung
titer
protect
death
mous
model
infect
recombin
viru
also
peptid
shown
potent
inhibitori
effect
hpivinduc
syncytium
format
target
specif
domain
f
protein
may
provid
use
antivir
approach
sever
hpiv
infect
gosh
shay
lambert
et
al
oral
parenter
steroid
also
appear
improv
croup
symptom
associ
moder
sever
hpiv
infect
somani
evan
hightit
pool
immunoglobulin
may
also
reduc
lower
respiratori
tract
infect
due
hpiv
prevent
studi
group
final
combin
immunotherapi
steroid
also
shown
reduc
pulmonari
viru
titer
inflamm
cotton
rat
model
princ
porter
strategi
could
constitut
therapeut
option
patient
sever
hpiv
diseas
effect
vaccin
antivir
avail
human
metapneumviru
hmpv
first
identifi
respiratori
tract
secret
dutch
children
bronchiol
van
den
hoogen
et
al
hmpv
caus
sever
respiratori
diseas
particularli
young
children
elderli
subject
immunocompromis
host
boivin
et
al
spectrum
diseas
epidemiolog
hmpv
resembl
hrsv
includ
upper
respiratori
tract
lower
respiratori
tract
ill
ie
cold
influenzalik
ill
bronchiol
croup
pneumonia
exacerb
asthma
chronic
obstruct
pulmonari
diseas
hamelin
et
al
hamelin
et
al
sever
pediatr
studi
hmpv
found
second
third
caus
hospit
young
children
hrsv
possibl
influenza
hamelin
et
al
current
approv
vaccin
hmpv
although
recombin
liveattenu
vaccin
gener
revers
genet
shown
promis
anim
studi
biacchesi
et
al
ribavirin
similar
vitro
activ
hmpv
hrsv
valu
approxim
respect
wyde
et
al
drug
also
decreas
hmpv
lung
titer
administ
intraperiton
rout
mice
hamelin
et
al
viral
inhibit
also
shown
heparin
sulfat
sialyl
lipid
two
drug
seem
alter
viral
fusion
assay
cell
cultur
wyde
et
al
human
monoclon
antibodi
hrsv
palizumab
vitro
activ
hmpv
wherea
convent
immunoglobulin
prepar
seem
contain
suffici
amount
neutral
titer
wyde
et
al
clinic
studi
antivir
immunoprophylact
agent
treatment
hmpv
infect
picornavirus
constitut
divers
famili
nonenvelop
singlestrand
positivesens
rna
virus
whose
genom
encod
singl
polyprotein
aa
macki
three
genera
within
famili
rhinoviru
enteroviru
parechoviru
caus
respiratori
tract
infect
human
human
rhinovirus
hrv
frequent
caus
mild
upper
respiratori
tract
infect
ie
common
cold
makela
et
al
savolainen
et
al
genu
includ
serotyp
divid
two
group
basi
cellular
receptor
major
rhinovirus
serotyp
use
intracellular
adhes
molecul
cell
receptor
viru
attach
wherea
remain
serotyp
use
low
densiti
lipoprotein
ldl
receptor
macki
temper
climat
hrv
infect
observ
throughout
year
although
peak
activ
fall
spring
season
makela
et
al
besid
common
cold
hrv
caus
acut
otiti
media
lower
respiratori
tract
infect
includ
pneumonia
wheez
children
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
adult
savolainen
et
al
enterovirus
echo
coxsackievirus
parechovirus
associ
numer
clinic
syndrom
includ
respiratori
tract
infect
vaccin
specif
immunoglobulin
respiratori
picornavirus
interferon
glycoprotein
induc
number
antivir
antiprolif
immunolog
effect
collect
affect
hostcel
suscept
picornaviru
infect
rotbart
et
al
conjunct
doublestrand
rna
interferon
induc
express
protein
mediat
antivir
activ
interferon
may
also
contribut
humor
antibodi
macrophag
elimin
picornaviru
infect
balfour
commerci
prepar
interferon
alpha
oral
bioavail
need
given
intramuscular
subcutan
inject
intranas
interferon
found
activ
clinic
prophylact
studi
hrv
infect
demonstr
benefit
treatment
establish
infect
mckinlay
furthermor
nasal
irrit
bleed
major
side
effect
limit
use
rotbart
pleconaril
propyl
phenyl
trifluoromethyl
oral
bioavail
antipicornavir
agent
pevear
et
al
act
integr
caviti
viral
capsid
inhibit
uncoat
thu
block
attach
hostcel
receptor
inhibit
viral
replic
pevear
et
al
pleconaril
demonstr
potent
broad
spectrum
activ
hrv
serotyp
cultur
enteroviru
serotyp
mckinlay
pleconaril
exhibit
median
valu
gml
test
select
hrv
serotyp
clinic
hrv
isol
kaiser
et
al
pharmacokinet
studi
adult
children
shown
plasma
concentr
drug
concentr
inhibit
hrv
vitro
oral
administr
pevear
et
al
clinic
trial
pleconaril
confer
reduct
symptom
sever
durat
individu
natur
occur
cold
ison
et
al
recent
studi
shown
clinic
benefit
correl
drug
suscept
baselin
viru
isol
pevear
et
al
pleconariltr
subject
infect
highli
suscept
virus
gml
experienc
median
reduct
symptom
durat
day
compar
placebotr
subject
contrast
subject
whose
baselin
viru
isol
suscept
gml
benefit
pleconaril
treatment
prophylact
studi
picornaviru
respiratori
infect
pleconaril
associ
increas
menstrual
irregular
subsequ
concern
rais
drug
might
increas
metabol
reduc
efficaci
hormon
contracept
drug
use
treat
hiv
webster
result
pleconaril
licens
fda
intranas
formul
drug
investig
biota
inc
anoth
capsidfunct
inhibitor
shown
potent
antivir
activ
select
hrv
serotyp
median
valu
gml
also
effect
test
clinic
hrv
isol
n
median
valu
gml
agent
high
bioavail
evalu
rodent
dog
accumul
nasal
tissu
dog
mean
concentr
nasal
epithelium
h
dose
time
higher
plasma
concentr
significantli
higher
hrv
valu
recombin
solubl
tremacamra
boehring
mannheim
bind
competit
viral
receptor
hrv
vitro
thu
prevent
attach
subsequ
replic
shigeta
moreov
random
clinic
trial
experiment
infect
volunt
agent
signific
impact
total
symptom
score
reduc
proport
subject
clinic
cold
reduc
total
nasal
mucu
weight
reduc
turner
et
al
addit
antivir
appear
well
toler
protein
picornavirus
proteas
cleav
viral
precursor
polypeptid
structur
protein
enzym
essenti
viral
replic
rotbart
ruprintrivir
agouron
pharmaceut
inc
potent
inhibitor
hrv
proteas
vitro
effici
inhibit
hrv
serotyp
test
mean
valu
rang
patick
et
al
prophylact
studi
reduc
incid
cold
total
symptom
score
respiratori
symptom
nasal
discharg
kaiser
et
al
moreov
ruprintrivir
provid
reduct
total
respiratori
symptom
day
subject
start
treatment
within
h
less
onset
respiratori
symptom
schmidt
et
al
mild
nausea
tast
disturb
common
advers
effect
munoz
et
al
hand
intranas
spray
ruprintrivir
seem
well
toler
bloodting
mucu
nasal
irrit
common
side
effect
coronavirus
first
isol
year
ago
organ
cultur
human
embryon
trachea
nasal
epithelium
primari
human
kidney
cell
cultur
tyrrel
byno
virus
singlestrand
positivesens
rna
genom
approxim
kb
consid
largest
known
autonom
replic
rna
thiel
et
al
twothird
genom
encod
protein
involv
replic
transcript
viral
rna
three
group
coronavirus
includ
sever
anim
virus
five
human
virus
fig
human
coronavirus
hcov
consid
second
caus
common
cold
hrv
account
approxim
mild
upper
respiratori
infect
adult
falsey
et
al
viru
respons
sever
acut
respiratori
syndrom
sar
outbreak
identifi
new
coronaviru
sarscov
led
infect
death
countri
ksiazek
et
al
peiri
et
al
clinic
sar
character
system
symptom
fever
myalgia
follow
respiratori
symptom
includ
nonproduct
cough
dyspnea
approxim
case
deterior
requir
mechan
ventil
due
develop
acut
respiratori
distress
syndrom
ard
recent
hcovnl
associ
small
number
case
bronchiol
pneumon
human
fouchier
et
al
woo
et
al
b
current
approv
vaccin
specif
immunoglobulin
prevent
human
coronavirus
although
sever
group
work
develop
effect
vaccin
use
differ
approach
zhu
time
sar
outbreak
specif
treatment
shown
prevent
diseas
progress
howev
research
field
intensifi
result
certain
promis
thera
peutic
strategi
still
need
valid
subsequ
outbreak
sever
small
clinic
studi
assess
effect
ribavirin
sarscov
howev
none
clearli
demonstr
clinic
efficaci
groneberg
et
al
furthermor
drug
activ
sarscov
vitro
addit
knowl
et
al
report
common
advers
effect
individu
treat
highdos
ribavirin
therapi
suspect
probabl
sar
ie
haemolyt
anemia
hypocalcemia
hypomagnesemia
report
case
respect
combin
hiv
proteas
inhibitor
lopinavir
ritonavir
kaletra
abbott
laboratori
could
potenti
use
treatment
sar
agent
shown
antivir
activ
sarscov
vitro
chan
et
al
chu
et
al
small
group
patient
receiv
lopinavirritonavir
initi
treatment
signific
reduct
intub
mortal
rate
chan
et
al
chu
et
al
also
evalu
lopinavirritonavir
treatment
compar
histor
control
patient
also
treat
ribavirin
steroid
develop
ard
death
within
day
significantli
lower
lopinavirritonavir
group
compar
histor
control
nosocomi
infect
also
reduc
activ
group
proteas
inhibitor
may
consid
treatment
sar
vitro
activ
sarscov
includ
nelfinavir
calpain
inhibitor
iii
zvalphealacho
calpain
inhibitor
iv
valleucho
yamamoto
et
al
fusion
inhibitor
promis
candid
treatment
sar
postul
heptad
region
spike
protein
sarscov
involv
mechan
mediat
fusion
viru
hostcel
membran
analog
heptad
region
protein
provid
basi
antihiv
fusion
inhibitor
one
peptid
within
heptad
region
spike
protein
sarscov
specif
inhibit
viral
replic
vitro
addit
standard
antivir
agent
studi
report
highdos
steroid
associ
improv
chest
xray
oxygen
rate
fever
although
clinic
valu
still
uncertain
context
sar
addit
use
associ
joint
pain
caus
avascular
necrosi
groneberg
et
al
rna
interfer
therapi
process
small
interf
rna
sirna
mediat
specif
degrad
mrna
ident
sequenc
specif
sirna
target
replicas
region
sarscov
demonstr
strong
inhibitori
effect
replic
differ
strain
sarscov
vitro
et
al
howev
clinic
benefit
await
evalu
adenovirus
ad
nonenvelop
doublestrand
dna
virus
first
observ
human
adenoid
tissu
fiftyon
serotyp
human
ad
classifi
six
group
af
base
biolog
characterist
tumorigen
dna
homolog
despit
multiorgan
tropism
type
ad
predilect
respiratori
tract
caus
wide
rang
respiratori
symptom
includ
coryza
pharyng
tonsil
bronchiti
pneumonia
ad
belong
subgroup
b
c
e
account
respiratori
tract
infect
young
children
ruuskanen
et
al
also
signific
caus
acut
respiratori
diseas
militari
recruit
wadel
erdman
et
al
serotyp
part
live
adenoviru
vaccin
ad
found
associ
season
observ
respiratori
virus
although
caus
sporad
outbreak
diseas
gener
ad
infect
mild
selflimit
resolv
within
week
without
longterm
complic
howev
ad
constitut
import
caus
mortal
morbid
immunocompromis
children
neonat
munoz
et
al
azbug
levin
adenoviru
pneumonia
associ
mortal
rate
high
bone
marrow
transplant
recipi
hierhozl
despit
fact
live
entericco
oral
vaccin
develop
significantli
lower
ad
morbid
product
discontinu
howev
us
depart
defens
recent
award
contract
barr
laboratori
inc
resum
product
vaccin
blasiol
et
al
approv
therapeut
agent
ad
infect
howev
broad
spectrum
antivir
use
treatment
sever
ad
infect
immunocompromis
host
intraven
iv
ribavirin
shown
appar
success
treatment
ad
diseas
children
includ
stem
cell
transplant
sct
recipi
pneumonia
howard
et
al
bone
marrow
transplant
bmt
recipi
gastroenter
kapelushnik
et
al
leukem
children
dissemin
diseas
mccarthi
et
al
although
report
anecdot
small
seri
case
common
advers
effect
iv
ribavirin
revers
mild
anemia
rare
symptomat
cidofovir
broad
spectrum
cytosin
nucleotid
analogu
shown
efficaci
treat
symptomat
adassoci
diseas
immunocompromis
children
adult
ribaud
et
al
bordigoni
et
al
studi
sct
patient
age
year
patient
treat
cidofovir
recov
compar
patient
treat
ribavirin
bordigoni
et
al
howev
clinic
use
iv
cidofovir
limit
nephrotox
prevent
control
respiratori
viral
infect
remain
major
clinic
goal
impact
societi
term
health
qualiti
life
economi
notabl
except
influenza
virus
approv
vaccin
prevent
respiratori
viral
infect
despit
continu
effort
field
howev
immunoprophylact
agent
respigam
synagi
constitut
effect
strategi
prevent
sever
hrsv
infect
prematur
atrisk
infant
similarli
except
antiinfluenza
agent
includ
adamantan
amantadin
rimantadin
neuraminidas
inhibitor
zanamivir
oseltamivir
licens
antivir
larg
varieti
clinic
import
respiratori
virus
hpiv
hrv
ad
although
ribavirin
approv
treatment
hrsv
infect
clinic
use
limit
side
effect
combin
minor
clinic
efficaci
respiratori
viral
infect
selflimit
due
lack
rapid
pointofcar
diagnost
method
commerci
antivir
agent
respiratori
virus
repres
import
challeng
nevertheless
numer
antivir
agent
shown
potent
vitro
vivo
activ
differ
famili
respiratori
virus
merit
addit
studi
